Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Author(s): Roshani Patil and Sanjay Sharma*

DOI: 10.2174/0113895575293447240424052516

DownloadDownload PDF Flyer Cite As
Chemistry, Analysis, and Biological Aspects of Daprodustat, A New Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor: A Comprehensive Review

Page: [1847 - 1855] Pages: 9

  • * (Excluding Mailing and Handling)

Abstract

Background: The National Health and Nutrition Examination Survey (NHANES) carried out a survey between 2007-10 and found that as compared to the general population, the prevalence of anemia in chronic kidney disease (CKD) patients was twice high. Daprodustat is an investigational novel drug for the treatment of renal anemia.

Objective: The objective of this study is to provide a comprehensive review of chemistry, synthesis, pharmacology, pharmacokinetic, and bioanalytical methods for the analysis of Daprodustat.

Methods: To improve understanding, a review was carried out by creating a database of relevant prior research from electronic sources such as ScienceDirect and PubMed. The methodology is shown in the flowchart of the literature selection process.

Results: The drug was approved in 2020 for therapeutic purposes in Japan. It is a novel drug approved for the treatment of anemia in chronic kidney disease for oral administration. It is intended for adults who have undergone dialysis for a minimum of four months and are experiencing anemia as a result of chronic kidney disease.

Conclusion: This review examines therapeutic, pharmacological, and analytical aspects related to the novel drug Daprodustat.

[1]
Locatelli, F.; Del Vecchio, L. Quality of life: A crucial aspect for the patients, a neglected goal in the treatment of anemia in patients with CKD. Kidney Int., 2023, 103(6), 1025-1027.
[http://dx.doi.org/10.1016/j.kint.2023.03.026] [PMID: 37210194]
[2]
Mehdi, U.; Toto, R.D. Anemia, diabetes, and chronic kidney disease. Diabetes Care, 2009, 32(7), 1320-1326.
[http://dx.doi.org/10.2337/dc08-0779] [PMID: 19564475]
[3]
Portolés, J.; Martín, L.; Broseta, J.J.; Cases, A. Anemia in chronic kidney disease: From pathophysiology and current treatments, to future agents. Front. Med., 2021, 8642296
[http://dx.doi.org/10.3389/fmed.2021.642296] [PMID: 33842503]
[4]
St Peter, W.L.; Guo, H.; Kabadi, S.; Gilbertson, D.T.; Peng, Y.; Pendergraft, T.; Li, S. Prevalence, treatment patterns, and healthcare resource utilization in medicare and commercially insured non-dialysis-dependent chronic kidney disease patients with and without anemia in the United States. BMC Nephrol., 2018, 19(1), 67.
[http://dx.doi.org/10.1186/s12882-018-0861-1] [PMID: 29544446]
[5]
Akbari, A.; Clase, C.M.; Acott, P.; Battistella, M.; Bello, A.; Feltmate, P.; Grill, A.; Karsanji, M.; Komenda, P.; Madore, F.; Manns, B.J.; Mahdavi, S.; Mustafa, R.A.; Smyth, A.; Welcher, E.S. Canadian society of nephrology commentary on the KDIGO clinical practice guideline for CKD evaluation and management. Am. J. Kidney Dis., 2015, 65(2), 177-205.
[http://dx.doi.org/10.1053/j.ajkd.2014.10.013] [PMID: 25511161]
[6]
Fishbane, S.; Spinowitz, B. Update on anemia in ESRD and earlier stages of CKD: Core curriculum 2018. Am. J. Kidney Dis., 2018, 71(3), 423-435.
[http://dx.doi.org/10.1053/j.ajkd.2017.09.026] [PMID: 29336855]
[7]
Macdougall, I.C.; Eckardt, K.U.; Locatelli, F. Latest US KDOQI anaemia guidelines update what are the implications for Europe? Nephrol. Dial. Transplant., 2007, 22(10), 2738-2742.
[http://dx.doi.org/10.1093/ndt/gfm562] [PMID: 17906324]
[8]
Summary, E. Executive summary. Am. J. Kidney Dis., 2006, 47, S11-S15.
[http://dx.doi.org/10.1053/j.ajkd.2006.03.010] [PMID: 16678659]
[9]
Collins, A.J.; Li, S.; Gilbertson, D.T.; Liu, J.; Chen, S.C.; Herzog, C.A. Chronic kidney disease and cardiovascular disease in the medicare population. Kidney Int., 2003, 64(87), S24-S31.
[http://dx.doi.org/10.1046/j.1523-1755.64.s87.5.x] [PMID: 14531770]
[10]
Thomas, M.C.; Tsalamandris, C.; MacIsaac, R.J.; Jerums, G. The epidemiology of hemoglobin levels in patients with type 2 diabetes. Am. J. Kidney Dis., 2006, 48(4), 537-545.
[http://dx.doi.org/10.1053/j.ajkd.2006.06.011] [PMID: 16997049]
[11]
Herzog, C.A.; Muster, H.A.; Li, S.; Collins, A.J. Impact of congestive heart failure, chronic kidney disease, and anemia on survival in the medicare population. J. Card. Fail., 2004, 10(6), 467-472.
[http://dx.doi.org/10.1016/j.cardfail.2004.03.003] [PMID: 15599836]
[12]
van Nooten, F.E.; Green, J.; Brown, R.; Finkelstein, F.O.; Wish, J. Burden of illness for patients with non-dialysis chronic kidney disease and anemia in the United States: Review of the literature. J. Med. Econ., 2010, 13, 241-256.
[http://dx.doi.org/10.3111/13696998.2010.484307]
[13]
Stone, W.J.; Graber, S.E.; Krantz, S.B.; Dessypris, E.N.; O’Neil, V.L.; Olsen, N.J.; Pincus, T.P. Treatment of the anemia of predialysis patients with recombinant human erythropoietin: A randomized, placebo-controlled trial. Am. J. Med. Sci., 1988, 296(3), 171-179.
[http://dx.doi.org/10.1097/00000441-198809000-00005] [PMID: 3177433]
[14]
Gupta, N.; Wish, J.B. Hypoxia-inducible factor prolyl hydroxylase inhibitors: A potential new treatment for anemia in patients with CKD. Am. J. Kidney Dis., 2017, 69(6), 815-826.
[http://dx.doi.org/10.1053/j.ajkd.2016.12.011] [PMID: 28242135]
[15]
Daprodustat: Uses, interactions, mechanism of action. Available from: https://go.drugbank.com/drugs/DB11682[cited 2024 Mar 4].
[16]
CDER. Highlights of prescribing information., Available from: www.fda.gov/medwatch
[17]
Labes, R.; Brinkmann, L.; Kulow, V.A.; Roegner, K.; Mathia, S.; Balcerek, B.; Persson, P.B.; Rosenberger, C.; Fähling, M. Daprodustat prevents cyclosporine-A–mediated anemia and peritubular capillary loss. Kidney Int., 2022, 102(4), 750-765.
[http://dx.doi.org/10.1016/j.kint.2022.04.025] [PMID: 35643373]
[18]
Solid state forms of daprodustat and process for preparation thereof. U.S. Patent 20210387952A1, 2019.
[19]
Prolyl hydroxylase inhibitors - Google Patents . C.A. Patent 2655491A1, 2019.
[20]
Crystal form of Daprodustat, preparation method therefor and use thereof. W.O. Patent 2021031102, 2019.
[21]
Chen, J.; Shou, X.; Xu, Y.; Jin, L.; Zhu, C.; Ye, X.; Mei, Z.; Chen, P. A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease. Aging, 2023, 15(6), 2237-2274.
[http://dx.doi.org/10.18632/aging.204611] [PMID: 36988549]
[22]
Huang, Q.; You, M.; Huang, W.; Chen, J.; Zeng, Q.; Jiang, L.; Du, X.; Liu, X.; Hong, M.; Wang, J. Comparative effectiveness and acceptability of HIF prolyl-hydroxylase inhibitors versus for anemia patients with chronic kidney disease undergoing dialysis: A systematic review and network meta-analysis. Front. Pharmacol., 2023, 141050412
[http://dx.doi.org/10.3389/fphar.2023.1050412] [PMID: 37521459]
[23]
Imai, E.; Imai, A. The comparison between vadadustat and daprodustat regarding dose, cost, and safety of treatment for renal anemia in non-dialysis patients with chronic kidney diseases. Intern. Med., 2024, 2501-2523.
[http://dx.doi.org/10.2169/internalmedicine.2501-23] [PMID: 37926547]
[24]
Sackeyfio, A.; Lopes, R.D.; Kovesdy, C.P.; Cases, A.; Mallett, S.A.; Ballew, N.; Keeley, T.J.; Garcia-Horton, V.; Ayyagari, R.; Camejo, R.R.; Johansen, K.L.; Sutton, A.J.; Dasgupta, I. Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populations. Clin. Kidney J., 2024, 17(1)sfad298
[http://dx.doi.org/10.1093/ckj/sfad298] [PMID: 38250252]
[25]
Prolyl hydroxylase inhibitors - Google patents. W.O. Patent 2007150011A2, 2007.
[26]
Ariazi, J.L.; Duffy, K.J.; Adams, D.F.; Fitch, D.M.; Luo, L.; Pappalardi, M.; Biju, M.; DiFilippo, E.H.; Shaw, T.; Wiggall, K.; Erickson-Miller, C. Discovery and preclinical characterization of GSK1278863 (Daprodustat), a small molecule hypoxia inducible factor–prolyl hydroxylase inhibitor for anemia. J. Pharmacol. Exp. Ther., 2017, 363(3), 336-347.
[http://dx.doi.org/10.1124/jpet.117.242503] [PMID: 28928122]
[27]
Yeh, T.L.; Leissing, T.M.; Abboud, M.I.; Thinnes, C.C.; Atasoylu, O.; Holt-Martyn, J.P.; Zhang, D.; Tumber, A.; Lippl, K.; Lohans, C.T.; Leung, I.K.H.; Morcrette, H.; Clifton, I.J.; Claridge, T.D.W.; Kawamura, A.; Flashman, E.; Lu, X.; Ratcliffe, P.J.; Chowdhury, R.; Pugh, C.W.; Schofield, C.J. Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials. Chem. Sci., 2017, 8(11), 7651-7668.
[http://dx.doi.org/10.1039/C7SC02103H] [PMID: 29435217]
[28]
Caltabiano, S.; Cizman, B.; Burns, O.; Mahar, K.M.; Johnson, B.M.; Ramanjineyulu, B.; Serbest, G.; Cobitz, A.R. Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure. Clin. Kidney J., 2019, 12(5), 693-701.
[http://dx.doi.org/10.1093/ckj/sfz013] [PMID: 31583094]
[29]
Macdougall, I.C.; Akizawa, T.; Berns, J.S.; Bernhardt, T.; Krueger, T. Effects of molidustat in the treatment of anemia in CKD. Clin. J. Am. Soc. Nephrol., 2019, 14(1), 28-39.
[http://dx.doi.org/10.2215/CJN.02510218] [PMID: 30559105]
[30]
Mahar, K.M.; Caltabiano, S.; Andrews, S.; Ramanjineyulu, B.; Chen, L.; Young, G.; Pereira, A.; Lindsay, A.C.; van den Berg, F.; Cobitz, A.R. Clinical pharmacokinetics of daprodustat: Results of an absorption, distribution, and excretion study with intravenous microtracer and concomitant oral doses for bioavailability determination. Clin. Pharmacol. Drug Dev., 2021, 10(12), 1419-1431.
[http://dx.doi.org/10.1002/cpdd.1029] [PMID: 34713596]
[31]
Tai, G.; Xia, F.; Chen, C.; Pereira, A.; Pirhalla, J.; Miao, X.; Young, G.; Beaumont, C.; Chen, L. Investigation of the human metabolism and disposition of the prolyl hydrolase inhibitor daprodustat using IV microtracer with entero‐test bile string. Pharmacol. Res. Perspect., 2023, 11(6)e1145
[http://dx.doi.org/10.1002/prp2.1145] [PMID: 37885335]
[32]
Sanghani, N.S.; Haase, V.H. Hypoxia-inducible factor activators in renal anemia: Current clinical experience. Adv. Chronic Kidney Dis., 2019, 26(4), 253-266.
[http://dx.doi.org/10.1053/j.ackd.2019.04.004] [PMID: 31477256]
[33]
Yamada, M.; Osamura, M.; Ogura, H.; Onoue, T.; Wakamatsu, A.; Numachi, Y.; Caltabiano, S.; Mahar, K.M. A single‐dose, open‐label, randomized, two‐way crossover study in healthy japanese participants to evaluate the bioequivalence and the food effect on the pharmacokinetics of daprodustat. Clin. Pharmacol. Drug Dev., 2020, 9(8), 978-984.
[http://dx.doi.org/10.1002/cpdd.793] [PMID: 32250021]
[34]
Hara, K.; Takahashi, N.; Wakamatsu, A.; Caltabiano, S. Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects. Drug Metab. Pharmacokinet., 2015, 30(6), 410-418.
[http://dx.doi.org/10.1016/j.dmpk.2015.08.004] [PMID: 26643993]
[35]
Holdstock, L.; Meadowcroft, A.M.; Maier, R.; Johnson, B.M.; Jones, D.; Rastogi, A.; Zeig, S.; Lepore, J.J.; Cobitz, A.R. Four-week studies of oral hypoxia-inducible factor–prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. J. Am. Soc. Nephrol., 2016, 27(4), 1234-1244.
[http://dx.doi.org/10.1681/ASN.2014111139] [PMID: 26494831]
[36]
Brigandi, R.A.; Johnson, B.; Oei, C.; Westerman, M.; Olbina, G.; de Zoysa, J.; Roger, S.D.; Sahay, M.; Cross, N.; McMahon, L.; Guptha, V.; Smolyarchuk, E.A.; Singh, N.; Russ, S.F.; Kumar, S.; Borsukov, A.V.; Marasaev, V.V.; Prasad, G.; Timokhovskaya, G.Y.; Kolmakova, E.V.; Dobronravov, V.A.; Zakharova, E.V.; Abraham, G.; Packham, D.; Zateyshchikov, D.A.; Arutyunov, G.P.; Volgina, G.V.; Lipatov, K.S.; Perlin, D.V.; Cooper, B.; Kumar Saha, T.; Zagrebelnaya, O.A.; Mehta, K.S.; Koziolova, N.A.; Fassett, R.; Alexeeva, N.P.; Lysenko, L.V. A novel hypoxia-inducible factor−prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: A 28-day, phase 2a randomized trial. Am. J. Kidney Dis., 2016, 67(6), 861-871.
[http://dx.doi.org/10.1053/j.ajkd.2015.11.021] [PMID: 26827289]
[37]
Becker, K.A.; Jones, J.J. An emerging treatment alternative for anemia in chronic kidney disease patients: A review of daprodustat. Adv. Ther., 2018, 35(1), 5-11.
[http://dx.doi.org/10.1007/s12325-017-0655-z] [PMID: 29285707]
[38]
GSK receives first regulatory approval for Duvroq (daprodustat) in Japan for patients with anaemia due to chronic kidney disease. GSK , Available from: https://www.gsk.com/en-gb/media/press-releases/gsk-receives-first-regulatory-approval-for-duvroq-daprodustat-in-japan-for-patients-with-anaemia-due-to-chronic-kidney-disease/[cited 2024 Mar 3].
[39]
Tsubakihara, Y.; Akizawa, T.; Nangaku, M.; Onoue, T.; Yonekawa, T.; Matsushita, H.; Endo, Y.; Cobitz, A. A 24‐week anemia correction study of daprodustat in japanese dialysis patients. Ther. Apher. Dial., 2020, 24(2), 108-114.
[http://dx.doi.org/10.1111/1744-9987.12962] [PMID: 31306555]
[40]
Dhillon, S. Daprodustat: First approval. Drugs, 2020, 80(14), 1491-1497.
[http://dx.doi.org/10.1007/s40265-020-01384-y] [PMID: 32880805]
[41]
Guddat, S.; Solymos, E.; Orlovius, A.; Thomas, A.; Sigmund, G.; Geyer, H.; Thevis, M.; Schänzer, W. High‐throughput screening for various classes of doping agents using a new ‘dilute‐and‐shoot’ liquid chromatography‐tandem mass spectrometry multi‐target approach. Drug Test. Anal., 2011, 3(11-12), 836-850.
[http://dx.doi.org/10.1002/dta.372] [PMID: 22135086]
[42]
Mazzarino, M.; Perretti, I.; Stacchini, C.; Comunità, F.; de la Torre, X.; Botrè, F. UPLC–MS-based procedures to detect prolyl-hydroxylase inhibitors of HIF in urine. J. Anal. Toxicol., 2021, 45(2), 184-194.
[http://dx.doi.org/10.1093/jat/bkaa055] [PMID: 32435795]
[43]
Thevis, M.; Milosovich, S.; Licea-Perez, H.; Knecht, D.; Cavalier, T.; Schänzer, W. Mass spectrometric characterization of a prolyl hydroxylase inhibitor GSK1278863, its bishydroxylated metabolite, and its implementation into routine doping controls. Drug Test. Anal., 2016, 8(8), 858-863.
[http://dx.doi.org/10.1002/dta.1870] [PMID: 26361079]